Skip to main content

Dentsply Sirona Value Stock - Dividend - Research Selection

Dentsply sirona

ISIN: US24906P1093 , WKN: A2AF0E

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials. In addition, it provides dental technology products, including dental implants and related scanning equipment, treatment software, and orthodontic appliances for dental practitioners and specialist, and dental laboratories; and dental equipment, such as treatment centers, imaging equipment, and computer aided design and machining systems for dental practitioners and laboratories. Further, the company offers healthcare consumable products, such as urology catheters, various surgical products, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers to dentists, dental hygienists, dental assistants, dental laboratories, and dental schools; and urology products directly to patients, as well as through distributors to urologists, urology nurses, and general practitioners. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in York, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


1 Stock Under $50 to Research Further and 2 Facing Headwinds

2026-08-24
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11

2026-08-24
Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.

3 Unprofitable Stocks with Open Questions

2026-08-20
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?

2026-08-19
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

2026-08-19
Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.

How the U.K. VAT Ruling Could Reshape Align's 2026 Earnings Outlook

2026-08-17
Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.

The 5 Most Interesting Analyst Questions From Dentsply Sirona’s Q2 Earnings Call

2026-08-15
Dentsply Sirona’s second quarter results were met with a negative market reaction, as shares declined following revenue and non-GAAP earnings that exceeded Wall Street expectations. Management attributed the year-on-year revenue decline primarily to lower sales volumes in key product segments and regions, especially in the Americas and EMEA, and highlighted ongoing challenges in capital equipment demand and inventory reduction by distributor partners. CEO Daniel Scavilla described the company’s

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

2026-08-14
Revenue declined 4.1% as restructuring efforts begin to take hold.

Is NVST a Buy as Earnings Rebound but Valuation Remains Above Median?

2026-08-13
Envista's earnings rebound and raised 2026 guidance strengthen the case, but above-median valuation leaves less room for execution setbacks.

XRAY Q2 Deep Dive: Turnaround Progress Slowed by Market and Segment Headwinds

2026-08-11
Dental products company Dentsply Sirona (NASDAQ:XRAY) announced better-than-expected revenue in Q2 CY2026, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.